Long-term imatinib therapy promotes bone formation in CML patients

Area of Science:

• Biochemistry
• Oncology
• Bone Biology

Background:

• Imatinib targets tyrosine kinases crucial for osteoclast and osteoblast function.
• Long-term imatinib therapy may impact bone homeostasis, necessitating investigation.

Purpose of the Study:

• To evaluate the effect of imatinib on bone homeostasis in chronic myeloid leukemia (CML) patients.
• To investigate the in vitro mechanisms by which imatinib influences osteoblast function.

Main Methods:

• Measured trabecular bone volume (TBV) in iliac crest biopsies before and after 2-4 years of imatinib therapy in CML patients.
• Assessed serum calcium and phosphate levels.
• Utilized in vitro cell cultures to examine imatinib's effects on osteoblast proliferation, gene expression, and matrix production, focusing on PDGF receptor signaling and PI3-kinase/Akt pathway.

Main Results:

• 8 of 17 (47%) CML patients showed a >2-fold increase in TBV after imatinib treatment, often exceeding age-matched norms.
• Imatinib-treated patients exhibited reduced serum calcium and phosphate, with 53% experiencing hypophosphatemia.
• In vitro, imatinib suppressed osteoblast proliferation but stimulated osteogenic gene expression and matrix production by inhibiting PDGF receptor signaling, impacting Akt and Crk-L activation.

Conclusions:

• Imatinib therapy can lead to a significant increase in trabecular bone volume in CML patients.
• The observed bone increase may be linked to PI3-kinase/Akt pathway inhibition, promoting mineral formation.
• Further research is warranted to explore imatinib's potential as a therapeutic strategy for generalized bone loss conditions.